Should I Buy LSTA? LSTA 2026 Analysis

Should You Buy Lisata Therapeutics Inc (LSTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

4.540

1 Day change

-1.30%

52 Week Range

4.890

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: LSTA is trading at ~$4.70 while the announced acquisition consideration is $4.00 (plus non-tradeable rights), creating unfavorable deal-risk asymmetry for an impatient buyer.
Technicals are bullish but extremely overbought (RSI ~89.5), which raises near-term pullback risk versus limited upside unless a higher bid emerges.
News flow is dominated by M&A-related legal investigations, which is not a fundamental upside catalyst and often signals uncertainty around process/terms.
With no strong proprietary (Intellectia) buy signals today and weak underlying fundamentals (revenue ~0, losses widening), this is better treated as an avoid/sell rather than a fresh entry.

Technical Analysis

Trend: Bullish structure (SMA_5 > SMA_20 > SMA_200) suggests strong recent momentum.
Momentum/overbought: RSI_6 = 89.536 indicates a very stretched, overbought condition—often followed by consolidation or a pullback.
MACD: Histogram positive (0.121) but “positively contracting,” implying upside momentum is still positive but fading.
Levels:
- Pivot/support: ~4.454 (first area where dips may try to stabilize)
- Support: S1 ~4.121; S2 ~3.915
- Resistance: R1 ~4.787 (nearby); R2 ~4.993
Pattern-based projection: 60% chance of ~-0.63% next day; +2.05% next week; +7.72% next month—near-term skew is not attractive given the current overbought reading and deal overhang.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Potential upside only if the market expects an improved takeout price / competing bid (the main reason shares can trade above stated cash consideration).
- Bullish moving average stack can keep momentum traders engaged in the short term if the price holds above the pivot (~4.454).

Neutral/Negative Catalysts

is above the announced $4.00 cash component, so any deal reaffirmation/clarification can pressure the stock back toward deal terms.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 0 (no improvement indicated; effectively no operating revenue base).
Net income: -$4.249M, down ~13.81% YoY (losses worsened).
EPS: -0.49, down ~16.95% YoY (deteriorating).
Overall: fundamentals show ongoing losses with no revenue traction in the snapshot—does not support buying above deal-related pricing without a clear catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so no recent trend in Wall Street ratings/targets can be confirmed.
Practical “pros vs cons” view from available data:
- Pros: event-driven optionality if a higher bid emerges; strong recent momentum.
- Cons: weak financial profile (no revenue, losses widening) and current pricing suggests more downside-to-deal than upside unless new deal news appears.

Analyst Rating

Wall Street analysts forecast LSTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 4.600

Low

Averages

High

Current: 4.600

Low

Averages

High

Brookline

Buy

maintain

$20 -> $32

AI Analysis

2025-07-15

Reason